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ABSTRACT
Objective: Recent studies reported contrasting results
with respect to the presence of anti-myelin protein
antibodies in multiple sclerosis (MS) and their relation
with disease activity. This may be due to the
heterogeneous specificity of autoantibodies in MS and the
inability of most methods to detect pathogenically
relevant antibodies. Here, myelin particles were used to
detect anti-myelin antibodies in the CSF of MS patients.
Subsequently, their relation with MRI parameters was
evaluated.
Methods: Anti-myelin IgG antibody reactivity was
determined in the CSF of patients with MS (n = 65) and
clinically isolated syndrome (CIS, n = 37) using a novel
flow cytometry based assay. In addition, the CSF of
patients with other neurological diseases (OND, n = 17),
inflammatory neurological diseases (IND, n = 33) and
controls (n = 22) was tested.
Results: Compared with controls, increased anti-myelin
IgG antibody reactivity was most frequently found in the
CSF of patients with CIS (46%, p = 0.002), relapsing–
remitting MS (56%, p,0.001) and secondary progressive
MS (55%, p,0.001), together constituting 85% of all
positive CSF samples. In contrast, elevated anti-myelin
IgG antibody reactivity was present in a minority of IND
patients (21%), marginally present in controls (5%) and
absent in OND patients (0%). Most strikingly, anti-myelin
IgG antibody reactivity was related to the number of T2
lesions (r = 0.31, p = 0.041) and gadolinium enhancing
T1 lesions (r = 0.37, p = 0.016) on brain MRI in CIS and
relapse onset MS patients.
Conclusion: CSF anti-myelin IgG antibodies are promising
specific biomarkers in CIS and relapse onset MS and
correlate with MR measures of disease activity.
The pathogenesis of multiple sclerosis (MS)
involves the immune mediated degradation of
myelin, the fatty sheath that surrounds the nerve
fibres of the CNS.1 Several studies have suggested
that humoral immunity plays a role in the
pathogenesis of MS. Antibody deposition in MS
has been found to be associated with disintegration
of myelin around axons in lesions2 and transfer of
anti-myelin specific antibodies to animals with
experimental autoimmune encephalomyelitis
resulted in a more severe disease course.3 4 The
pathogenic role of antibodies in the demyelination
process involves activation of complement and
receptor mediated phagocytosis of myelin by
macrophages.5 6
Analysis of the pathology of MS lesions revealed
that in approximately 50% of MS patients, the
demyelination process showed close similarities to
antibody mediated autoimmune encephalomye-
litis.7 These patients are also more likely to respond
to therapeutic plasma exchange compared with
patients with other pathological patterns.8
However, clinical studies that characterised anti-
body responses in MS demonstrated contrasting
results with respect to the frequency of autoanti-
body positive MS patients. Myelin oligodendrocyte
glycoprotein (MOG) specific antibodies have been
detected in MS patients at variable frequencies,
ranging from as low as 6% to 38%.4 9 10 Recently,
O’Connor et al reported that anti-MOG antibodies
were only present in acute disseminated encephal-
omyelitis and almost undetectable in adult onset
MS patients.11 Similar contrasting results have
been obtained with respect to autoantibody levels
and MS disease activity and progression. Kuhle et al
recently reported that there was no association
between the presence of serum anti-MBP and anti-
MOG specific antibodies in patients who had a
clinically isolated syndrome (CIS) and their risk of
developing clinically definite MS,12 as was sug-
gested by a previous study.13 Another recent study
in a second CIS cohort of the same authors
confirmed the lack of prognostic value of these
antibodies for clinically definite MS.14 However,
patients with anti-MOG and anti-MBP antibodies
had higher lesion load and more disseminated
lesions in cranial MRI, which was in contrast with
a previous study that demonstrated no association
between anti-MOG and anti-MBP antibodies and
MRI findings at baseline and follow-up.15
A common problem encountered in these clinical
studies is that accurate detection of pathogenically
relevant antibodies requires a properly folded and
post-translationally modified target protein.16–18
Recombinant, in vitro translated and native
purified myelin proteins have been used for
detection of myelin specific antibodies.13 18–20
None of these methods takes into account the
specific structure of folded myelin proteins in
association with a hydrophobic, lipid-rich bilayer
membrane as they are displayed to the immune
system in vivo on myelin sheaths. Additionally,
antibody responses in MS are not restricted to a
single myelin protein but show a heterogeneous
specificity, including reactivity to myelin lipids.21
Therefore, autoantibody responses in MS may only
be partly or not at all detected by determination of
reactivity to a single myelin protein.
Recently, we described a novel flow cytometry
based assay that detects antibodies that bind to
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myelin particles, which have a bead-like appearance in aqueous
solution.22 The assay allows the simultaneous detection of anti-
myelin antibodies specific for a wide variety of myelin proteins
and lipids. In addition, myelin proteins and lipids are displayed
to the antibodies in a similar manner as they are presented in
vivo on an initial immune response. Here we demonstrate that
CSF anti-myelin IgG antibodies are increased in half of CIS
patients and in the majority of relapse onset MS patients
whereas they were absent in the CSF of controls and patients
with other neurological diseases. Most strikingly, the presence
of anti-myelin IgG antibodies in the CSF of CIS and relapse
onset MS patients was related to the number of T2 and
gadolinium enhancing T1 lesions on brain MRI.
MATERIALS AND METHODS
Isolation of human myelin
Human myelin was isolated as described previously.22 Briefly,
CNS white matter was homogenised in 0.32 M sucrose. The
suspension was layered over a 0.85 M solution of sucrose and
centrifuged at 75 000 g for 30 min at 4uC (step 1). The
interphase, containing the myelin, was pooled and washed
three times with deionised water by repeated centrifugation
(75 000 g, 15 min, 4uC) (step 2). Steps 1 and 2 were repeated
twice. Myelin was collected and stored at 220uC until further
use.
The protein concentration of the myelin preparation was
calculated using a bovine serum albumin standard curve, as
described previously.23 Myelin from five subjects was pooled and
used in all assays.
Myelin flow cytometry assay
We used the myelin flow cytometry assay, described previously
22. Briefly, human myelin (15 mg) and undiluted CSF (15 ml)
were added to 100 ml of phosphate buffered saline (PBS, pH 7.4)
in a 96 well V-bottom plate and incubated for 30 min at 37uC.
Unbound CSF proteins were removed by washing the myelin in
PBS (4500 rpm, 4 min; 36). Myelin particles were subsequently
incubated with biotinylated goat anti-human IgG (Jackson
Laboratories, West Grove, Pennsylvania, USA) for 30 min at
37uC. After washing in PBS, samples were incubated with
Alexa488/594 conjugated streptavidin (Molecular Probes, US),
washed again and taken up in 50 ml of PBS in FACS tubes
(B&D Biosciences, Franklin Lakes, New Jersey, USA). Myelin
immunoreactivity was measured using the FACS Calibur (B&D
Biosciences). Anti-myelin antibody levels were expressed as
mean fluorescence intensity (MFI). All CSF samples were
incubated with myelin in triplicate and all samples were
included in at least three separate experiments.
Patient and control characteristics
CSF samples were obtained from a CSF library stored at the
Neurological Clinic, Karolinska Hospital, KS. The library
contains CSF from patients having undergone diagnostic
lumbar punctures at the Neurological Clinic Karolinska
Hospital between 2001 and 2006. The majority of patients
participated in the STOP MS project. The samples have been
stored coded and made anonymous in accordance with the
Medical Research Council guidelines on the ethical use of
biological specimen collections in clinical research.
In all MS patients (n = 65), definite MS was diagnosed
according to the criteria of McDonald et al by trained
neurologists.24 Patients were classified as having a relapsing
remitting (RRMS, n = 36) or secondary progressive (SPMS,
n = 29) MS disease course according to Lublin and Reingold.25 A
trained neurologist scored the symptoms and signs of MS.
Disability was measured using the Expanded Disability Status
Scale (EDSS). Disease activity was based on clinical evaluation.
Exacerbation was defined as a decline in neurological status >1
grade on the EDSS, the symptoms of which had started more
than a week prior to sampling. Patients whose neurological
deficits had remained stable for the last month were regarded as
being in remission. CIS patients (n = 37) had a first clinical
episode with one or more MRI lesions characteristic of MS.
MRI data obtained within 2 months of CSF sampling were
included in this study (n = 52). The routine MRI examinations
were performed on a 1.5 T GE scanner with a birdcage head coil
(Sigma Lx or Excite) using the following sequences: sagittal and
axial fast spin echo (FSE), FLAIR, with 5 mm slices (no gaps) or
4 mm slices, respectively (TE/TR/TF 140/9000/12000). Axial
and sagittal fast spin echo T2 (TE/TR/echo train length = 85/
4500/11–12). Pre- and postcontrast axial, spin echo T1 (TE/TR
10/560) 5 mm slices with 2 mm gaps and 4 mm slices without
gaps, respectively. Post-contrast images approximately 5–6 min
after 0.1 mM/kg bodyweight Ominscan (GE Medical).
Isoelectric focusing with immunoblotting on agarose gels was
used for the detection of oligoclonal bands in CSF and serum
samples.
Three control groups were used. One group consisted of
patients with other neurological diseases (OND, n = 17), such as
normal pressure hydrocephalus (n = 3), brain tumours (n = 3),
migraine (n = 2), headache (n = 2), vertebral artery dissection
(n = 1), polyneuropathy (n = 1), neuralgia (n = 1), myasthenia
gravis (n = 1), dissociative motor disorder (n = 2) and vertigo
(n = 1). The group inflammatory neurological diseases (IND,
n = 33) consisted of patients with cerebral systemic lupus
erythematosus (SLE) (n = 14), post polio syndrome (n = 12),
herpes encephalitis (n = 3), unspecific encephalomyelitis (n = 2),
bacterial meningitis (n = 1) and cerebral vasculitis (n = 1). The
22 controls were analysed for various subjective conditions.
However, extensive clinical and ancillary investigations have
not revealed a neurological disease. The controls had normal
CSF cell counts, protein and glucose levels, and normal
neuroradiological examination. The local ethics committee
approved the study.
The patient subgroups and patient data were coded and
unknown to the investigator at the time of FACS analysis.
Preparation of cell free CSF
CSF was sampled in siliconised glass tubes. CSF samples were
centrifuged at 15006g for 10 min at 4uC (to remove cells and
other insoluble materials). The cell free CSF supernatant was
recovered in aliquots in polypropylene tubes and stored at
280uC until use.
Statistical analysis
It was technically not feasible to measure anti-myelin antibody
levels in all CSF samples within one experiment. However,
correlations between MFI values of CSF samples that were
included in consecutive experiments were high (Pearson’s Rho
0.8–1.0, p,0.001). Therefore, MFI values from two representa-
tive experiments were normalised and pooled for further
analysis. For normalisation, regression analysis was performed
on samples that were included in both experiments and the
regression line was used to normalise MFI values.
Differences in anti-myelin antibody levels between several
groups were analysed using the Kruskall–Wallis test. Differences
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between two groups were analysed by the Mann–Whitney test.
Anti-myelin antibody levels in individual MS CSF samples were
considered to be enhanced over control values when MFI was
higher than the mean value of controls +36SD). Differences in
the proportion of anti-myelin Ig positive samples were analysed
using the x2 test.
The relationship between anti-myelin antibody levels and
EDSS, disease duration and the number of T2 and gadolinium
enhancing T1 lesions was determined by Spearman’s correlation
analysis.
A p value lower than 0.05 was considered to indicate
statistical significance (confidence level 95%).
RESULTS
Increased anti-myelin IgG antibody reactivity in CSF of MS
patients
To determine whether anti-myelin antibodies were present in
the CSF of CIS and MS patients and patients with other
neurological diseases, myelin particles were incubated with CSF
samples, and binding of IgG antibodies was assessed by flow
cytometry analysis. Clinical characteristics of patients and
controls are summarised in table 1. Kruskall–Wallis analysis
revealed significantly (p,0.001) different MFI values between
the several patient groups with significantly (p,0.001)
increased MFI values in CIS and relapse onset MS patients
compared with controls and patients with other neurological
diseases (fig 1A). Next, individuals were considered to have
enhanced anti-myelin antibody levels if anti-myelin antibody
reactivity exceeded the average of controls +36SD. The number
Table 1 Patient characteristics
Subjects (n)
Age (years)
(mean (range))
Sex
(F/M)
EDSS
(median (range))
OGB
(Yes/No)
MS patients (65) 47 (19–82) 41/24 3.6 (0.0–8.0) 57/8
RRMS (36) 36 (19–54) 24/12 1.9 (0.0–4.0) 32/4
SPMS (29) 54 (24–82) 17/12 5.4 (3.0–8.0) 25/4
CIS patients (37) 35 (16–61) 28/9 1.5 (0.0–6.5) 26/10
HC (22)* 40 (22–61) 16/6 – 0/13
OND (17) 48 (25–83) 8/9 – 2/11
IND (33) 51 (13–75) 26/7 – 0/20
*HC are sex and age matched to the other patient groups with the exception of the
OND group (sex mismatched).
CIS, clinically isolated syndrome; EDSS, Expanded Disability Status Scale; HC, healthy
controls; IND, inflammatory neurological diseases; MS, multiple sclerosis; OGB,
oligoclonal bands; OND, other neurological diseases; RRMS, relapsing remitting
multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
Figure 1 Increased CSF IgG antibody reactivity to myelin in patients
with clinically isolated syndrome (CIS) and relapsing remitting (RRMS) or
secondary progressive (SPMS) multiple sclerosis (MS). IgG antibody
reactivity to myelin (A) and total IgG levels (B) were analysed in the CSF
of controls (HC, n = 22), in those with other neurological diseases (OND,
n = 17), inflammatory neurological diseases (IND, n = 33), CIS patients
(n = 37), and RRMS (n = 36) and SPMS (n = 29) patients. Myelin
particles were incubated with CSF, and antibody binding to myelin was
determined in each patient by secondary anti-human IgG antibodies and
quantified by flow cytometry. Differences in the frequency of anti-myelin-
positive patients were analysed using the x2 test. Mean fluorescence
intensity (MFI) differences between the patient groups were calculated
using Kruskall–Wallis non-parametric analysis. The line indicates the
mean MFI of HC +36SD. The percentage of subjects exceeding this
value is indicated above the graph.
Figure 2 Increased CSF anti-myelin IgG antibody reactivity in patients
with herpes encephalitis and a subpopulation of systemic lupus
erythematosus (SLE) patients. CSF IgG antibody reactivity to myelin was
analysed in the CSF of patients with inflammatory neurological diseases
(IND, n = 33). Myelin particles were incubated with CSF and antibody
binding to myelin was determined in each patient by secondary anti-
human IgG antibodies and quantified by flow cytometry. The line
indicates the mean fluorescence intensity (MFI) of healthy controls
+36SD.
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of patients with increased anti-myelin reactivity was signifi-
cantly increased in the IND patient group (21%, p = 0.018), the
CIS patient group (46%, p = 0.002), and the RRMS (56%,
p,0.001) and SPMS (55%, p,0.001) patient groups compared
with controls (fig 1A). The assay demonstrated the following
performance characteristics as a biomarker for diagnosis of
relapse onset (RR and SP) MS: sensitivity: 52% of relapse onset
MS patients exhibited elevated anti-myelin antibody reactivity;
specificity: 89% of control patients (controls/OND/IND) scored
negative in our assay; positive predictive value: 84% of positive
CSF samples were derived from RRMS and SPMS patients.
We previously shown that monoclonal antibodies directed
against the myelin proteins PLP, MBP and MOG induced a clear
shift in MFI whereas incubation of isotype matched control
antibodies or secondary antibodies did not induce a significant
shift in MFI, suggesting that antibodies bind specifically to the
myelin particles.22 As depicted in fig 1B, we also determined the
distribution of total CSF IgG antibody levels between the
several patient groups. Although Kruskall–Wallis analysis
revealed that total CSF IgG levels were significantly (p,0.001)
different between the several patient groups, there was no
significant difference between relapse onset MS patients and
OND patients, which is in contrast with the MFI results.
Additionally, the frequency of relapse onset MS patients with
increased CSF IgG levels was not significantly different from
OND patients. Normalisation of anti-myelin MFI values for IgG
levels revealed a significantly elevated MFI/IgG ratio in IND
(p = 0.001), CIS (p = 0.001), RRMS (p = 0.002) and SPMS
(p = 0.006) patients compared with OND patients.
Increased anti-myelin IgG antibody reactivity in CSF of patients
with CIS and IND
A substantial proportion of CIS patients (46%, fig 1) demon-
strated elevated anti-myelin antibody reactivity compared with
controls. Clinical follow-up data of these patients, with a
median clinical follow-up of 1 year, revealed that 12 out of 37
CIS patients developed clinically definite MS. Five out of these
12 patients (42%) had elevated CSF anti-myelin antibody
reactivity at the time of CIS diagnosis, which was very similar
to the frequency observed in the entire CIS patient group. Thus
these data suggest that CIS patients with a high CSF anti-
myelin antibody reactivity have no prevalence towards devel-
oping definite MS compared with CIS patients with low anti-
myelin antibody reactivity.
Anti-myelin IgG antibodies in seven out of 33 patients of the
IND group exceeded the mean of controls by 3 SDs (fig 2).
Three of these patients were diagnosed with cerebral SLE (29%
of entire cerebral SLE patient group). Remarkably, all three
patients with herpes simplex encephalitis had increased anti-
myelin IgG reactivity.
Increased anti-myelin IgG antibody reactivity in CIS and MS
patients with CSF oligoclonal bands
Next, we evaluated whether anti-myelin IgG antibody reactiv-
ity in CIS and MS patients was related to the presence of CSF
Figure 3 Increased anti-myelin IgG antibody reactivity in patients with
clinically isolated syndrome (CIS) and relapsing remitting (RRMS) or
secondary progressive (SPMS) multiple sclerosis (MS) with CSF
oligoclonal bands. Myelin particles were incubated with CSF derived
from CIS and MS patients. Antibody binding to myelin was determined in
each patient by secondary anti-human IgG antibodies and quantified by
flow cytometry. The difference in anti-myelin antibody reactivity
between patients with (right) and without (left) oligoclonal bands was
analysed using Mann–Whitney non-parametric analysis. The line
indicates the mean fluorescence intensity (MFI) of healthy controls
+36SD.
Figure 4 Significant correlation between anti-myelin IgG antibody
reactivity and lesions on brain MRI. Myelin particles were incubated with
CSF derived from patients with clinically isolated syndrome (CIS) and
relapse onset multiple sclerosis (n = 52). Antibody binding to myelin
was determined in each patient by secondary anti-human IgG antibodies
and quantified by flow cytometry. Anti-myelin mean fluorescence
intensity (MFI) values were plotted against the number of T2 lesions (A)
or gadolinium (gd) enhancing T1 lesions (B) detected on brain MRI.
Correlation analysis were performed using Spearman rank.
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oligoclonal bands. As depicted in fig 3, CIS and MS patients
with CSF oligoclonal bands showed significantly (p = 0.021)
increased anti-myelin antibody reactivity compared with
patients without oligoclonal bands. CSF IgG levels were also
significantly (p = 0.043) increased in patients with oligoclonal
bands compared with patients without bands, whereas the
MFI/IgG ratio was not significantly different (data not shown).
Anti-myelin antibody reactivity correlates with MR parameters of
disease activity in CIS and MS patients
Anti-myelin reactivity was significantly related to the number
of T2 lesions (r = 0.31, p = 0.041, fig 4A). A similar significant
correlation was observed between T2 lesions and CSF IgG levels
(r = 0.030, p = 0.043), whereas no significant relationship was
observed between the anti-myelin MFI/IgG ratio and T2 lesions
(data not shown). Anti-myelin antibody reactivity also sig-
nificantly correlated with gadolinium enhancing T1 lesions
(r = 0.37, p = 0.016; fig. 4B). In contrast, CSF IgG levels showed
no significant correlation (r = 0.18, p = 0.26) with T1 lesions,
whereas the anti-myelin MFI/IgG ratio correlated significantly
(r = 0.36, p = 0.020) with T1 lesions.
There was no cross sectional relation between EDSS scores or
disease duration and anti-myelin IgG antibody reactivity (data
not shown). In addition, we found no difference in anti-myelin
antibody reactivity between RRMS patients in remission and
those who underwent a relapse (data not shown).
DISCUSSION
The frequency of anti-myelin antibodies and their relation to
disease activity in MS patients is controversial. This is probably
because of the fact that most detection methods focus on
reactivity to a single myelin protein whereas anti-myelin
antibody responses in MS patients are very heterogeneous with
respect to their specificities.21 Moreover, relevant antibodies
may only be detected by methods that use conformational post-
translationally modified myelin epitopes whereas most methods
use denaturated or recombinant myelin proteins.13 18 19 Here we
used a novel flow cytometry based assay that detects antibody
reactivity to myelin particles, allowing the simultaneous
detection of a wide variety of myelin protein and lipid specific
antibodies. In addition, target epitopes are presented to the
antibodies in a similar manner as they are displayed in vivo to
autoreactive antibodies.
Using this method, we detected increased CSF antibody
reactivity to myelin in half of the CIS and relapse onset MS
patients. These results are similar to the frequency of MS
patients with antibody mediated autoimmunity based on the
pathology of MS lesions.7 Compared with other studies that
detected antibody responses to a single myelin protein, the
frequency of anti-myelin antibody positive MS patients in our
study is at least twice as high.4 9 10 This discrepancy may be
explained by the fact that detection of antibody responses to a
single myelin protein only covered part of all the different
autoantibody specificities in MS patients. For instance, the
recently identified myelin lipid specific antibodies are not
detected by these methods.21
The frequency of anti-myelin antibody positive CIS patients
that developed clinically definite MS was not different from the
frequency observed in the entire CIS patient group. Although it
should be noted that the median clinical follow-up in this cohort
was 1 year, these results are in agreement with recent studies,
showing that CIS patients with increased anti-MOG antibody
reactivity have no prevalence towards developing MS compared
with those without detectable anti-MOG antibodies.12 15
We also found anti-myelin antibody reactivity in one-fifth of
patients with inflammatory neurological diseases whereas
nearly all controls and patients with other neurological diseases
scored negative in our assay. Three out of seven positive IND
patients were diagnosed for herpes encephalitis. These patients
can easily be distinguished from MS patients based on clinical
symptoms and specific PCR analysis. Although the number of
patients is to small to draw conclusions, the coincidence of
herpes encephalitis and the presence of CSF anti-myelin
antibodies is interesting. Ferrante et al showed that herpes
simplex virus-1 DNA and mRNA was present in a significant
number of MS patients during clinical relapse.26 Other herpes
viruses, such as human herpesvirus 6 and Epstein–Barr virus,
have also been implicated to be associated with MS.27 Increased
antibody responses to human herpesvirus 6 and Epstein–Barr
virus have previously been detected in the blood and CSF of MS
patients.28 29 However, the fact that herpes infection by itself is
associated with the presence of CSF anti-myelin antibodies is an
interesting and novel finding. Further studies are required to
investigate the coincidence of virus infections and the occur-
rence of CSF anti-myelin antibodies.
The detection of CSF oligoclonal IgG is currently the most
useful, albeit unspecific, laboratory test to aid in the diagnosis of
MS.30 Oligoclonal IgG is synthesised within the CNS and is
present in about 90% of patients with clinically definite MS. In
this study, we demonstrated that anti-myelin antibodies were
predominantly enhanced in MS patients with oligoclonal bands,
indicating that oligoclonal bands may represent anti-myelin IgG
antibodies. However, anti-myelin antibodies could also be
detected in a substantial proportion (28%) of the CIS and MS
patients who had no CSF oligoclonal bands, suggesting that our
anti-myelin antibody assay may have added value to current
diagnostic CSF markers.
A number of findings suggest that different MFI values are a
result of specific binding of antibodies to myelin and not just a
reflection of different IgG levels. There is a clear discrepancy
between the frequency of MS patients with elevated IgG levels
and increased MFI values. In addition, CSF IgG levels in the
OND patient group were similar to IgG levels in the IND and
MS patient groups, whereas MFI values were highly different
between these patient groups. Finally, increased anti-myelin
antibody reactivity was associated with increased IgG levels in
the relapse onset MS patients only (r = 0.572, p = 0.001)
whereas no correlation was observed in the OND and IND
patient groups (r = 0.108 (p = 0.513), despite similar IgG levels
and fluctuations.
We also demonstrated that CSF anti-myelin IgG antibodies
were related to the number of T2 and gadolinium enhancing T1
lesions on brain MRI in CIS and relapse onset MS patients,
indicating that our assay has potential to monitor disease
activity (ie, active inflammation). Only limited clinical studies
evaluated the relation between anti-myelin antibodies and MR
measures in CIS and MS patients. Lim et al reported that anti-
MOG and anti-MBP antibodies in CIS patients were not
associated with MRI findings at baseline or after follow-up.15
In contrast, Kuhle et al recently reported that CIS patients with
anti-MOG and anti-MBP antibodies had more white matter
lesions than patients without these antibodies.14 However, the
majority of patients with one to nine lesions were negative for
anti-MOG and anti-MBP antibodies whereas the majority of
patients with comparable lesion number in our study were
antibody positive. Thus our assay may detect anti-myelin
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antibody responses at an early stage of the disease whereas anti-
MOG and anti-MBP responses may develop during later stages
of the disease.
Further studies in paired serum/CSF samples have to be
performed to evaluate whether the increased CSF anti-myelin
antibody reactivity is intrathecally produced. Additionally, it
remains to be elucidated whether the autoreactive anti-myelin
antibodies contribute to the pathogenesis of MS. Our findings
that increased anti-myelin antibody reactivity in CSF of relapse
onset MS patients correlate with disease activity at an early
stage of the disease are in agreement with a potential role of
these antibodies in pathogenesis of MS. Alternatively, anti-
myelin antibodies may merely represent an epiphenomenon
that develops in response to continuous myelin breakdown.
However, regardless of whether anti-myelin antibodies are
causative or not, we clearly demonstrated that anti-myelin
antibodies, detected with myelin particles, have potential as
specific and promising biomarkers for MS disease activity.
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